David A. Siegel Arrowhead Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 102,100 shares of ARWR stock, worth $1.96 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
102,100
Previous 38,800
163.14%
Holding current value
$1.96 Million
Previous $1.11 Million
139.22%
% of portfolio
0.01%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding ARWR
# of Institutions
295Shares Held
92.3MCall Options Held
1.33MPut Options Held
549K-
Black Rock Inc. New York, NY15.7MShares$301 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$234 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.89MShares$170 Million3.15% of portfolio
-
State Street Corp Boston, MA5.84MShares$112 Million0.01% of portfolio
-
Slate Path Capital LP New York, NY4.14MShares$79.4 Million2.11% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $2.03B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...